Antidepressants and Risk of Type 2 Diabetes Mellitus A Population-Based Nested Case-Control Study

doi:10.1097/JCP.0000000000001228

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24891

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24891

Title:	Antidepressants and Risk of Type 2 Diabetes Mellitus A Population-Based Nested Case-Control Study
Authors:	Kuo, HY;Chen, HM;Lee, CC;Lee, HH;Kuo, CJ;Hsu, CS;Pan, CC;Su, N;Chu, CS
Keywords:	antidepressant;depression;diabetic mellitus;serotonin transporter
Date:	2020
Issue Date:	2022-08-09T08:09:40Z (UTC)
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
ISSN:	0271-0749
Abstract:	Purpose/Background The increased risk of type 2 diabetes mellitus (T2DM) among users of antidepressants (ADs) might be mediated by depression. We investigated whether ADs are associated with increased risk of T2DM in patients with depression. Moreover, the relationship between binding affinities of serotonin transporter (SERT) of ADs and the risk of T2DM is examined. Methods/Procedures We conducted a retrospective nested case-control study using data from Taiwan's National Health Insurance Research Database between 2000 and 2013. A total of 3038 patients with depression, 1519 cases of T2DM, and 1519 controls matched for age, sex, and index date, were included. Exposure to ADs was categorized by type and SERT. The association between AD exposure and T2DM development was assessed using conditional logistic regression analysis. Findings/Results No association between T2DM development and selective serotonin reuptake inhibitors (adjusted odds ratio [AOR], 1.01; 95% confidence interval [CI], 0.87-1.19;P= 0.962), serotonin-norepinephrine reuptake inhibitors (AOR, 1.13; 95% CI, 0.94-1.37;P= 1.196), tricyclic antidepressants (AOR, 1.01; 95% CI, 0.85-1.21;P= 0.906), or others (AOR, 0.88; 95% CI, 0.75-1.03;P= 0.104) was found. Alternatively, no association between individual ADs and potency of affinity to SERT and the risk of T2DM was found. Implications/Conclusions No association between ADs and increase risk of T2DM was found in patients with depression. However, regular metabolic evaluations are recommended for patients with depression regularly taking ADs.
URI:	http://dx.doi.org/10.1097/JCP.0000000000001228 https://www.webofscience.com/wos/woscc/full-record/WOS:000549914100009 https://ir.csmu.edu.tw:8080/handle/310902500/24891
Relation:	JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY ,2020 ,v40 ,issue 4 ,p359-365
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	158	View/Open

Loading...